Analyst Price Targets — NBIX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 11:56 am | — | Bernstein | $218.00 | $156.49 | TheFly | Neurocrine price target lowered to $218 from $221 at Bernstein |
| August 13, 2026 11:36 am | — | Morgan Stanley | $182.00 | $156.49 | TheFly | Neurocrine price target lowered to $182 from $196 at Morgan Stanley |
| August 13, 2026 8:26 am | — | Deutsche Bank | $165.00 | $156.49 | TheFly | Neurocrine price target lowered to $165 from $190 at Deutsche Bank |
| August 3, 2026 12:18 pm | — | Wedbush | $194.00 | $170.06 | TheFly | Neurocrine price target raised to $194 from $185 at Wedbush |
| August 3, 2026 10:54 am | Andrew Fein | H.C. Wainwright | $215.00 | $166.80 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX) |
| August 3, 2026 10:41 am | Sumant Kulkarni | Canaccord Genuity | $210.00 | $166.80 | StreetInsider | Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord |
| July 31, 2026 1:05 pm | — | Morgan Stanley | $196.00 | $167.38 | TheFly | Neurocrine price target raised to $196 from $193 at Morgan Stanley |
| July 31, 2026 12:54 pm | David Hoang | Deutsche Bank | $190.00 | $165.93 | TheFly | Neurocrine price target raised to $190 from $170 at Deutsche Bank |
| July 31, 2026 11:45 am | — | Needham | $204.00 | $185.50 | TheFly | Neurocrine price target raised to $204 from $200 at Needham |
| July 31, 2026 11:34 am | GAAP EPS | Piper Sandler | $210.00 | $185.50 | TheFly | Neurocrine price target raised to $210 from $207 at Piper Sandler |
Latest News for NBIX
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,986 shares of the company's stock, valued at approximately $1,009,000. Other institutional investors and hedge
Allworth Financial LP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,853 shares of the company's stock, valued at approximately $2,503,000. A number of other hedge funds
Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NBIX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.